Preclinical Pharmacokinetic and Pharmacological Studies of Antitumor and other Th

SRI国际提供了一个持续的资源进行以下类型的研究与代理选定的临床前开发通过上述程序：（1）开发灵敏的分析方法，以量化化合物在血浆，尿液，组织，和其他生物基质;（2）血浆稳定性和蛋白结合研究，在化合物开发的早期阶段进行，以确保适当的样品处理并帮助解释体内研究;（3）在通过各种途径和时间表给予动物后对测试化合物的药代动力学评价，包括通过各种途径测定生物利用度;（4）体内和各种体外系统中产生的药物代谢物的定量和鉴定（S9组分、微粒体、肝细胞、P450亚型、肝切片）;和（5）化合物对推定分子靶点的作用（药效学作用）与化合物暴露的相关性。

SRI international provides a continuing resource for conducting the following types of studies with agents selected for preclinical development through the programs listed above: (1) development of sensitive analytical methods to quantify compounds in plasma, urine, tissues, and other biological matrices; (2) plasma stability and protein binding studies, which are conducted at an early stage of compound development to ensure proper sample handling and to aid in the interpretation of in vivo studies; (3) pharmacokinetic evaluation of test compounds following administration to animals by various routes and schedules, including a determination of bioavailability by various routes; (4) quantification and identification of drug metabolites generated in vivo and in various in vitro systems (S9 fractions, microsomes, hepatocytes, P450 isoforms, liver slices); and (5) correlation of compound effects on putative molecular targets (pharmacodynamic effects) with compound exposures.